ArticleFrontiers in microbiology2026
Neutrophil CD64 index for diagnosing and tracking treatment response across the mycobacterial infection spectrum: a retrospective two-cohort study.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The neutrophil CD64 (nCD64) index has emerged as a promising biomarker for infection detection, but its evaluation within the mycobacterial infection spectrum remains limited. Here, we evaluated the diagnostic and treatment response performance of the nCD64 index in the active tuberculosis (ATB)-including pulmonary tuberculosis (PTB) and extrapulmonary tuberculosis (ePTB), and non-tuberculous mycobacterial (NTM) disease, and determined whether it adds value beyond standard inflammatory indicators. Methods: We measured the nCD64 index in a cross-sectional cohort comprising 248 participants across five groups: ATB, latent tuberculosis infection (LTBI), NTM, bacterial pulmonary infection (PI) and healthy donors (HD). Patients with ATB and NTM had not received anti-mycobacterial treatment at the time of enrollment. Diagnostic performance was assessed by receiver operating characteristic (ROC) curve analysis, and incremental value beyond white blood cell (WBC) count and C-reactive protein (CRP) was evaluated by comparing an area under the curve (AUC) with and without nCD64 index. In a separate longitudinal cohort of 244 participants, nCD64 index was measured at baseline and months 1-3 of anti-mycobacterial therapy, and longitudinal trajectories were compared between treatment-naive and retreatment patients using a linear mixed-effects (LME) model. Results: nCD64 index was markedly elevated in ATB compared to all other groups (all Conclusion: The nCD64 index discriminates ATB from LTBI and NTM, adds diagnostic value beyond routine inflammatory markers, and tracks serial changes during treatment in both ATB and NTM. Treatment-naive patients showed more pronounced decline trajectories, supporting particular utility of the nCD64 index for tracking initial treatment response. It warrants further evaluation as a complementary biomarker in the clinical management of mycobacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.